A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct

Journal of Medicinal Chemistry

Volumn 55, Issue 12, 2012, Pages 5878-5886

  Wolfe, Amanda L ^a   Duncan, Katharine K ^a   Parelkar, Nikhil K ^b   Weir, Scott J ^b   Vielhauer, George A ^b   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (BENZYLOXY) 5 BROMO 2 NAPHTHOIC ACID; CARBAMIC ACID DERIVATIVE; DUOCARMYCIN CARBAMATE; DUOCARMYCIN DERIVATIVE; ETHYL 4 (BENZYLOXY) 5 BROMO 2 NAPHTHOATE; ETHYL 5 BROMO 4 HYDROXY 2 NAPHTHOATE; N [2 (5 AMINO 4 OXO 1,2,9,9A TETRAHYDROCYCLOPROPA[C] BENZO[E]INDOL 2 CARBONYL) 1H INDOL 5 YL] 1H INDOLE 2 CARBOXAMIDE; N [2 [10 (CHLOROMETHYL) 5 OXO 5,8,9,10 TETRAHYDRO 4H PYRROLO[3',2':5,6]NAPHTHO[1,8 DE][1,3]OXAZINE 8 CARBONYL] 1H INDOL 5 YL] 1H INDOLE 2 CARBOXAMIDE; RACHELMYCIN; TERT BUTYL 1,2 DIHYDRO 5 (BENZYLOXY) 6 BROMO 1 (CHLOROMETHYL) 1H BENZO[E]INDOLE 3(2H) CARBOXYLATE; TERT BUTYL 1,2 DIHYDRO 6 AMINO 1 (CHLOROMETHYL) 5 HYDROXY 1H BENZO[E]INDOLE 3(2H) CARBOXYLATE; TERT BUTYL 10 (CHLOROMETHYL) 5 OXO 9,10 DIHYDRO 4H PYRROLO[3',2':5,6]NAPHTHO[1,8 DE][1,3]OXAZINE 8(5H) CARBOXYLATE; TERT BUTYL [4 (BENZYLOXY) 5 BROMO 1 IODONAPHTHALEN 2 YL] (3 CHLOROALLYL)CARBAMATE; TERT BUTYL [4 (BENZYLOXY) 5 BROMO 1 IODONAPHTHALEN 2 YL] CARBAMATE; TERT BUTYL [4 (BENZYLOXY) 5 BROMONAPHTHALEN 2 YL] CARBAMATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYDROLYSIS; MOUSE; NONHUMAN; SUSTAINED DRUG RELEASE; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBAMATES; CELL LINE, TUMOR; CYCLOPROPANES; DRUG DESIGN; HUMANS; HYDROLYSIS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; PRODRUGS; PYRROLIDINONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863084739     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300330b     Document Type: Article

References (86)

1. Ichimura, M.; Ogawa, T.; Takahashi, K.; Kobayashi, E.; Kawamoto, I.; Yasuzawa, T.; Takahashi, I.; Nakano, H. Duocarmycin SA, a New Antitumor Antibiotic from Streptomyces sp J. Antibiot. 1990, 43, 1037-1038
2. Martin, D. G.; Biles, C.; Gerpheide, S. A.; Hanka, L. J.; Krueger, W. C.; McGovren, J. P.; Mizsak, S. A.; Neil, G. L.; Stewart, J. C.; Visser, J. CC-1065 (NSC 298223), a Potent New Antitumor Agent. Improved Production and Isolation, Characterization and Antitumor Activity J. Antibiot. 1981, 34, 1119-1125
3. Takahashi, I.; Takahashi, K.; Ichimura, M.; Morimoto, M.; Asano, K.; Kawamoto, I.; Tomita, F.; Nakano, H. Duocarmycin, a New Antitumor Antibiotic from Streptomyces J. Antibiot. 1988, 41, 1915-1917
4. Igarashi, Y.; Futamata, K.; Fujita, T.; Sekine, A.; Senda, H.; Naoki, H.; Furumai, T. Yatakemycin, a Novel Antifungal Antibiotic Produced by Streptomyces sp. TP-A0356 J. Antibiot. 2003, 56, 107-113
5. Boger, D. L.; Johnson, D. S.; Yun, W. (+)- and ent -(-)-Duocarmycin SA and (+)- and ent -(-)-N-BOC-DSA DNA Alkylation Properties. Alkylation Site Models That Accommodate the Offset AT-Rich Adenine N3 Alkylation Selectivity of the Enantiomeric Agents J. Am. Chem. Soc. 1994, 116, 1635-1656
6. Parrish, J. P.; Kastrinsky, D. B.; Wolkenberg, S. E.; Igarashi, Y.; Boger, D. L. DNA Alkylation Properties of Yatakemycin J. Am. Chem. Soc. 2003, 125, 10971-10976
7. Trzupek, J. D.; Gottesfeld, J. M.; Boger, D. L. Alkylation of Duplex DNA in Nucleosome Core Particles by Duocarmycin SA and Yatakemycin Nat. Chem. Biol. 2006, 2, 79-82
8. Tichenor, M. S.; MacMillan, K. S.; Trzupek, J. D.; Rayl, T. J.; Hwang, I.; Boger, D. L. Systematic Exploration of the Structural Features of Yatakemycin Impacting DNA Alkylation and Biological Activity J. Am. Chem. Soc. 2007, 129, 10858-10869
9. Hurley, L. H.; Lee, C.-S.; McGovren, J. P.; Warpehoski, M. A.; Mitchell, M. A.; Kelly, R. C.; Aristoff, P. A. Molecular Basis for Sequence-Specific DNA Alkylation by CC-1065 Biochemistry 1988, 27, 3886-3892
10. Boger, D. L.; Johnson, D. S.; Yun, W.; Tarby, C. M. Molecular Basis for Sequence Selective DNA Alkylation by (+)- and ent -(-)-CC-1065 and Related Agents: Alkylation Site Models That Accommodate the Offset AT-Rich Adenine N3 Alkylation Selectivity Bioorg. Med. Chem. 1994, 2, 115-135
11. Boger, D. L.; Munk, S. A.; Zarrinmayeh, H. (+)-CC-1065-DNA Alkylation: Key Studies Demonstrating a Noncovalent Binding Selectivity Contribution to the Alkylation Selectivity J. Am. Chem. Soc. 1991, 113, 3980-3983
12. Boger, D. L.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Suntornwat, O. Demonstration of a Pronounced Effect of Noncovalent Binding Selectivity on the (+)-CC-1065 DNA Alkylation and Identification of the Pharmacophore of the Alkylation Subunit Proc. Nat. Acad. Sci. U.S.A. 1991, 88, 1431-1435
13. 3. Preparation of Key Partial Structures and Definition of an Additional Functional Role of the CC-1065 Central and Right-Hand Subunits J. Am. Chem. Soc. 1990, 112, 4623-4632
14. Boger, D. L.; Munk, S. A.; Ishizaki, T. (+)-CC-1065 DNA Alkylation: Observation of an Expected Relationship between Cyclopropane Electrophile Reactivity and the Efficiency of DNA Alkylation J. Am. Chem. Soc. 1991, 113, 2779-2780
15. Boger, D. L.; Coleman, R. S.; Invergo, B. J.; Zarrinmayeh, H.; Kitos, P. A.; Thompson, S. C.; Leong, T.; McLaughlin, L. W. A Demonstration of the Intrinsic Importance of Stabilizing Hydrophobic Binding and Noncovalent van der Waals Contacts Dominant in the Noncovalent CC-1065:DNA Binding Chem.-Biol. Interact. 1990, 73, 29-52
16. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Suntornwat, O. Duocarmycin-Pyrindamycin DNA Alkylation Properties and Identification, Synthesis, and Evaluation of Agents Incorporating the Pharmacophore of the Duocarmycin-Pyrindamycin Alkylation Subunit. Identification of the CC-1065 Duocarmycin Common Pharmacophore J. Am. Chem. Soc. 1990, 112, 8961-8971
17. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H. Isolation and Characterization of the Duocarmycin-Adenine DNA Adduct J. Am. Chem. Soc. 1991, 113, 6645-6649
18. Boger, D. L.; Yun, W.; Terashima, S.; Fukuda, Y.; Nakatani, K.; Kitos, P. A.; Jin, Q. DNA Alkylation Properties of the Duocarmycins: (+)-Duocarmycin A, epi -(+)-Duocarmycin A, ent -(-)-Duocarmycin A and epi, ent -(-)-Duocarmycin A Bioorg. Med. Chem. Lett. 1992, 2, 759-765
19. Boger, D. L.; Yun, W. Reversibility of the Duocarmycin A and SA DNA Alkylation Reaction J. Am. Chem. Soc. 1993, 115, 9872-9873
20. Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins: Understanding Their Biological Function through Mechanistic Studies Angew. Chem., Int. Ed. Engl. 1996, 35, 1438-1474
21. Boger, D. L. The Duocarmycins: Synthetic and Mechanistic Studies Acc. Chem. Res. 1995, 28, 20-29
22. Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins: Unraveling the Keys to a New Class of Naturally Derived DNA Alkylating Agents Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3642-3649
23. Boger, D. L.; Garbaccio, R. M. Shape-Dependent Catalysis: Insights into the Source of Catalysis for the CC-1065 and Duocarmycin DNA Alkylation Reaction Acc. Chem. Res. 1999, 32, 1043-1052
24. Tichenor, M. S.; Boger, D. L. Yatakemycin: Total Synthesis, DNA Alkylation, and Biological Properties Nat. Prod. Rep. 2008, 25, 220-226
25. MacMillan, K. S.; Boger, D. L. Fundamental Relationships between Structure, Reactivity, and Biological Activity for the Duocarmycins and CC-1065 J. Med. Chem. 2009, 52, 5771-5780
26. Searcey, M. Duocarmycins: Nature's Prodrugs? Curr. Pharm. Des. 2002, 8, 1375-1389
27. Tse, W. C.; Boger, D. L. Sequence-Selective DNA Recognition: Natural Products and Nature's Lessons Chem. Biol. 2004, 11, 1607-1617
28. Boger, D. L.; Coleman, R. S. Total Synthesis of (+)-CC-1065 and ent -(-)-CC-1065 J. Am. Chem. Soc. 1988, 110, 1321-1323
29. 2 J. Am. Chem. Soc. 1988, 110, 4796-4807
30. Boger, D. L.; Machiya, K. Total Synthesis of (+)-Duocarmycin SA J. Am. Chem. Soc. 1992, 114, 10056-10058
31. Boger, D. L.; Machiya, K.; Hertzog, D. L.; Kitos, P. A.; Holmes, D. Total Synthesis and Preliminary Evaluation of (+)- and ent -(-)-Duocarmycin SA J. Am. Chem. Soc. 1993, 115, 9025-9036
32. Boger, D. L.; McKie, J. A.; Nishi, T.; Ogiku, T. Enantioselective Total Synthesis of (+)-Duocarmycin A, epi -(+)-Duocarmycin A, and Their Unnatural Enantiomers J. Am. Chem. Soc. 1996, 118, 2301-2302
33. Boger, D. L.; McKie, J. A.; Nishi, T.; Ogiku, T. Total Synthesis of (+)-Duocarmycin A and epi -(+)-Duocarmycin A and Their Unnatural Enantiomers: Assessment of Chemical and Biological Properties J. Am. Chem. Soc. 1997, 119, 311-325
34. Tichenor, M. S.; Kastrinsky, D. B.; Boger, D. L. Total Synthesis, Structure Revision, and Absolute Configuration of (+)-Yatakemycin J. Am. Chem. Soc. 2004, 126, 8396-8398
35. Tichenor, M. S.; Trzupek, J. D.; Kastrinsky, D. B.; Shiga, F.; Hwang, I.; Boger, D. L. Asymmetric Total Synthesis of (+)- and ent -(-)-Yatakemycin and Duocarmycin SA. Evaluation of Yatakemycin Key Partial Structures and Its Unnatural Enantiomer J. Am. Chem. Soc. 2006, 128, 15683-15696
36. MacMillan, K. S.; Nguyen, T.; Hwang, I.; Boger, D. L. Total Synthesis and Evaluation of iso -Duocarmycin SA and iso -Yatakemycin J. Am. Chem. Soc. 2009, 131, 1187-1194
37. Boger, D. L.; Hertzog, D. L.; Bollinger, B.; Johnson, D. S.; Cai, H.; Goldberg, J.; Turnbull, P. Duocarmycin SA Shortened, Simplified, and Extended Agents: A Systematic Examination of the Role of the DNA Binding Subunit J. Am. Chem. Soc. 1997, 119, 4977-4986
38. Boger, D. L.; Bollinger, B.; Hertzog, D. L.; Johnson, D. S.; Cai, H.; Mesini, P.; Garbaccio, R. M.; Jin, Q.; Kitos, P. A. Reversed and Sandwiched Analogs of Duocarmycin SA: Establishment of the Origin of the Sequence-Selective Alkylation of DNA and New Insights into the Source of Catalysis J. Am. Chem. Soc. 1997, 119, 4987-4998
39. Boger, D. L.; Garbaccio, R. M. Catalysis of the CC-1065 and Duocarmycin DNA Alkylation Reaction: DNA Binding Induced Conformational Change in the Agent Results in Activation Bioorg. Med. Chem. 1997, 5, 263-276
40. 2: Enhanced Functional Analogs of CC-1065 Incorporating the 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI) Left-Hand Subunit J. Org. Chem. 1990, 55, 5823-5832
41. 2: CC-1065 Functional Agents Incorporating the Equivalent 1,2,9,9a-Tetrahydrocyclopropa[1,2- c ]benz[1,2- e ]indol-4-one (CBI) Left-Hand Subunit J. Am. Chem. Soc. 1989, 111, 6461-6463
42. 2: Enhanced Functional Analogs of (+)-CC-1065. A Critical Appraisal of a Proposed Relationship between Electrophile Reactivity, DNA Binding Properties, and Cytotoxic Potency Tetrahedron Lett. 1990, 31, 793-796
43. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H.; Kitos, P. A.; Suntornwat, O. A Potent, Simple Derivative of an Analog of the CC-1065 Alkylation Subunit Bioorg. Med. Chem. Lett. 1991, 1, 55-58
44. Boger, D. L.; Munk, S. A. DNA Alkylation Properties of Enhanced Functional Analogs of CC-1065 Incorporating the 1,2,9,9a-Tetrahydrocyclopropa[1, 2- c ]benz[1,2- e ]indol-4-one (CBI) Alkylation Subunit J. Am. Chem. Soc. 1992, 114, 5487-5496
45. 2 Substituent: Validation of a Direct Relationship between Solvolysis Chemical Stability and in Vitro Biological Potency J. Am. Chem. Soc. 1994, 116, 5523-5524
46. 1: CC-1065 Analogs Containing Deep-Seated Modifications in the DNA Binding Subunit Bioorg. Med. Chem. 1995, 3, 761-775
47. Boger, D. L.; Yun, W. CBI-TMI: Synthesis and Evaluation of a Key Analog of the Duocarmycins. Validation of a Direct Relationship between Chemical Solvolytic Stability and Cytotoxic Potency and Confirmation of the Structural Features Responsible for the Distinguishing Behavior of Enantiomeric Pairs of Agents J. Am. Chem. Soc. 1994, 116, 7996-8006
48. Parrish, J. P.; Katrinsky, D. B.; Stauffer, F.; Hedrick, M. P.; Hwang, I.; Boger, D. L. Establishment of Substitution Effects in the DNA Binding Subunit of CBI Analogues of the Duocarmycins and CC-1065 Bioorg. Med. Chem. 2003, 11, 3815-3838
49. Parrish, J. P.; Hughes, T. V.; Hwang, I.; Boger, D. L. Establishing the Parabolic Relationship between Reactivity and Activity for Derivatives and Analogues of the Duocarmycin and CC-1065 alkylation Subunit J. Am. Chem. Soc. 2004, 126, 80-81
50. Boger, D. L.; Yun, W.; Teegarden, B. R. An Improved Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI): A Simplified Analog of the CC-1065 Alkylation Subunit J. Org. Chem. 1992, 57, 2873-2876
51. Boger, D. L.; McKie, J. A. An Efficient Synthesis of 1,2,9,9a- Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI): An Enhanced and Simplified Analog of the CC-1065 and Duocarmycin Alkylation Subunits J. Org. Chem. 1995, 60, 1271-1275
52. Boger, D. L.; McKie, J. A.; Boyce, C. W. Asymmetric Synthesis of the 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI) Alkylation Subunit of CC-1065 and Duocarmycin Analogues Synlett 1997, 515-517
53. Kastrinsky, D. B.; Boger, D. L. Effective Asymmetric Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[ e ]benz[ e ]indol-4-one (CBI) J. Org. Chem. 2004, 69, 2284-2289
54. Lajiness, J. P.; Boger, D. L. Asymmetric Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI) J. Org. Chem. 2010, 76, 583-587
55. Boger, D. L.; Yun, W.; Han, N. 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI) Analogs of CC-1065 and the Duocarmycins: Synthesis and Evaluation Bioorg. Med. Chem. 1995, 3, 1429-1453
56. 2: An Enhanced Functional Analog of CC-1065 Bioorg. Med. Chem. Lett. 1991, 1, 115-120
57. Li, L.; DeKoning, T. F.; Kelly, R. C.; Krueger, W. C.; McGovren, J. P.; Padbury, G. E.; Petzold, G. L.; Wallace, T. L.; Ouding, R. J.; Prairie, M. D.; Gebhard, I. Cytotoxicity and Antitumor Activity of Carzelesin, a Prodrug Cyclopropylpyrroloindole Analogue Cancer Res. 1992, 52, 4904-4913
58. van Tellingen, O; Nooijen, W. J.; Schaaf, L. J.; van der Valk, M.; van Asperen, J.; Henrar, R. E. C.; Beijnen, J. H. Comparative Pharmacology of the Novel Cyclopropylpyrroloindole-Prodrug Carzelesin in Mice, Rats, and Humans Cancer Res. 1998, 58, 2410-2416
59. Kobayashi, E.; Okamoto, A.; Asada, M.; Okabe, M.; Nagamura, S.; Asai, A.; Saito, H.; Gomi, K.; Hirata, T. Characteristics of Antitumor Activity of KW-2189, a Novel Water-Soluble Derivative of Duocarmycin, against Murine and Human Tumors Cancer Res. 1994, 54, 2404-2410
60. Nagamura, S.; Kanda, Y.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Duocarmycin Derivatives Chem. Pharm. Bull. 1995, 43, 1530-1535
61. Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Searcey, M.; Jin, Q. CBI Prodrug Analogs of CC-1065 and the Duocarmycins Synthesis 1999, 1505-1509
62. Li, L. S.; Sinha, S. C. Studies toward the Duocarmycin Prodrugs for the Antibody Prodrug Therapy Approach Tetrahedron Lett. 2009, 50, 2932-2935
63. Tietze, L. F.; Lieb, M.; Herzig, T.; Haunert, F.; Schuberth, I. A Strategy for Tumor-Selective Chemotherapy by Enzymatic Liberation of seco-Duocarmycin SA-Derivatives from Nontoxic Prodrugs Bioorg. Med. Chem. 2001, 9, 1929-1939
64. Tietze, L. F.; Major, F.; Schuberth, I. Antitumor Agents: Development of Highly Potent Glycosidic Duocarmycin Analogues for Selective Cancer Therapy Angew. Chem., Int. Ed. 2006, 45, 6574-6577
65. Tietze, L. F.; Schuster, H. J.; Schmuck, K.; Schuberth, I.; Alves, F. Duocarmycin-Based Prodrugs for Cancer Prodrug Monotherapy Bioorg. Med. Chem. 2008, 16, 6312-6318
66. Hay, M. P.; Anderson, R. F.; Ferry, D. M.; Wilson, W. R.; Denny, W. A. Synthesis and Evaluation of Nitroheterocyclic Carbamate Prodrugs for Use with Nitroreductase-Mediated Gene-Directed Enzyme Prodrug Therapy J. Med. Chem. 2003, 46, 5533-5545
67. Hay, M. P.; Sykes, B. M.; Denny, W. A.; Wilson, W. R. A 2-Nitroimidazole Carbamate Prodrug of 5-Amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl) carbonyl]-1,2-dihydro-3 H -benz[ e ]indole (Amino-seco-CBI-TMI) for Use With ADEPT and GDEPT Bioorg. Med. Chem. Lett. 1999, 9, 2237-2242
68. Tercel, M.; Atwell, G. J.; Yang, S.; Ashoorzadeh, A.; Stevenson, R. J.; Botting, K. J.; Gu, Y.; Mehta, S. Y.; Denny, W. A.; Wilson, W. R.; Pruijn, F. B. Selective Treatment of Hypoxic Tumor Cells in Vivo: Phosphate Pre-Prodrugs of Nitro Analogues of the Duocarmycins Angew. Chem., Int. Ed. 2011, 50, 2606-2609
69. Townes, H.; Summerville, K.; Purnell, B.; Hooker, M.; Madsen, E.; Hudson, S.; Lee, M. Investigation of a Novel Reductively-Activatable Anticancer Prodrug of seco -CBI-TMI, an Analog of Duocarmycin SA Med. Chem. Res. 2002, 11, 248-253
70. Boger, D. L.; Garbaccio, R. M. A Novel Class of CC-1065 and Duocarmycin Analogues Subject to Mitomycin-Related Reductive Activation J. Org. Chem. 1999, 64, 8350-8362
71. Wang, Y.; Li, L.; Tian, Z.; Jiang, W.; Larrick, J. Synthesis and Antitumor Activity of CBI-Bearing Ester and Carbamate Prodrugs of CC-1065 Bioorg. Med. Chem. 2006, 14, 7854-7861
72. Zhao, R. H.; Erickson, H. K.; Leece, B. A.; Reid, E. E.; Goldmacher, V. S.; Lambert, J. M.; Chari, R. V. J. Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer J. Med. Chem. 2012, 55, 766-782
73. Jin, W.; Trzupek, J. D.; Rayl, T. J.; Broward, M. A.; Vielhauer, G. A.; Weir, S. J.; Hwang, I.; Boger, D. L. A Unique Class of Duocarmycin and CC-1065 Analogues Subject to Reductive Activation J. Am. Chem. Soc. 2007, 129, 15391-15397
74. Lajiness, J. P.; Robertson, W. M.; Dunwiddie, I.; Broward, M. A.; Vielhauer, G. A.; Weir, S. J.; Boger, D. L. Design, Synthesis, and Evaluation of Duocarmycin O -Amino Phenol Prodrugs Subject to Tunable Reductive Activation J. Med. Chem. 2010, 53, 7731-7738
75. Wolkenberg, S. E.; Boger, D. L. Mechanisms of in Situ Activation for DNA Targeting Antitumor Agents Chem. Rev. 2002, 102, 2477-2495
76. Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Goldberg, J. A. CC-1065 and the Duocarmycins: Synthetic Studies Chem. Rev. 1997, 97, 787-828
77. Boger, D. L.; Han, N.; Tarby, C. M.; Boyce, C. W.; Cai, H.; Jin, Q.; Kitos, P. A. Synthesis, Chemical Properties, and Preliminary Evaluation of Substituted CBI Analogs of CC-1065 and the Duocarmycins Incorporating the 7-Cyano-1,2,9,9a-tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one Alkylation Subunit: Hammett Quantitation of the Magnitude of Electronic Effects on Functional Reactivity J. Org. Chem. 1996, 61, 4894-4912
78. Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Searcey, M. Synthesis of CC-1065 and Duocarmycin Analogs via Intramolecular Aryl Radical Cyclization of a Tethered Vinyl Chloride Tetrahedron Lett. 1998, 39, 2227-2230
79. Boger, D. L.; Brotherton, C. E. Total Synthesis of Azafluoranthene Alkaloids: Refescine and Imelutine J. Org. Chem. 1984, 49, 4050-4055
80. Wolfe, A. L. Unpublished studies.
81. Huang, X.; Buchwald, S. L. New Ammonia Equivalents for the Pd-Catalyzed Amination of Aryl Halides Org. Lett. 2001, 3, 3417-3419
82. Boger, D. L.; Panek, J. S. Palladium(0)-Mediated β-Carboline Synthesis: Preparation of the CDE Ring System of Lavendamycin Tetrahedron Lett. 1984, 25, 3175-3178
83. Boger, D. L.; Duff, S. R.; Panek, J. S.; Yasuda, M. Inverse Electron Demand Diels-Alder Reactions of Heterocyclic Azadienes. Studies on the Total Synthesis of Lavendamycin: Investigative Studies on the Preparation of the CDE β-Carboline Ring System and AB Quinoline-5,8-quinone Ring System J. Org. Chem. 1985, 50, 5782-5789
84. Boger, D. L.; Panek, J. S.; Duff, S. R.; Yasuda, M. Total Synthesis of Lavendamycin Methyl Ester J. Org. Chem. 1985, 50, 5790-5795
85. 32-End-Labeled Double-Stranded DNA for Binding Studies. Development of a Protocol for Examination of Functional Features of (+)-CC-1065 and the Duocarmycins That Contribute to Their Sequence-Selective DNA Alkylation Properties Tetrahedron 1991, 47, 2661-2682
86. 2: CC-1065 Functional Analogs Incorporating the Parent 1,2,7,7a- Tetrahydrocyclopropa[1,2- c ]indol-4-one (CI) Left-Hand Subunit J. Am. Chem. Soc. 1990, 112, 5230-5240